Reversal of cognitive decline in Alzheimer's disease.
Level 4 - case-series / case-control
Case series of 10 patients without a control group
PubMed 27294343 · doi:10.18632/aging.100981
What was done
Ten patients with cognitive decline (subjective cognitive impairment, mild cognitive impairment, or early Alzheimer's disease; nine ApoE4-positive and one ApoE4-negative) received a personalized, multi-component intervention termed metabolic enhancement for neurodegeneration (MEND) for 5 to 24 months. Outcomes were evaluated via quantitative MRI, neuropsychological testing, and functional reports.
What was found
The abstract provides no numerical test scores, imaging measurements, or statistical values. It reports qualitatively that patients demonstrated improvements on neuropsychological testing and quantitative MRI, and that patients who had discontinued or struggled with work returned to work or improved their performance.
Why it matters
This report describes a multi-component metabolic protocol for cognitive decline, serving as early hypothesis-generating case-series evidence.
Limits
The study is an uncontrolled, unblinded case series of only 10 patients. Without a control group, the observed changes cannot be distinguished from practice effects, regression to the mean, or placebo response. No specific numerical data or effect sizes are provided in the abstract.
Cited by
- partial Recent research demonstrates that dementia can be reversed.